GlassScriptPhysician profile
Sofia P Miranda-Pasqualini
NPI 1235799727
$21,532.01
in general payments reported to CMS, 2019-2025
55 companies · $9,795 in 2025
The $9,795 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,449 · 2022: $1,011 · 2023: $6,127 · 2024: $3,150 · 2025: $9,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $5,858 · Travel and Lodging: $2,928 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,282.44 |
| Consulting Fee | $5,857.50 |
| Travel and Lodging | $2,928.27 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,149.03 | 2021-2025 | |
| Ucb, INC. | $1,083.82 | 2022-2024 | Briviact, Fintepla, Nayzilam |
| Livanova USA, INC. | $994.18 | 2023 | Vns Therapy |
| Emd Serono, INC. | $953.28 | 2022-2023 | Mavenclad |
| Abbvie INC. | $906.51 | 2021-2024 | |
| Eli Lilly and Company | $900.00 | 2021 | |
| Mdd US Operations, LLC | $663.99 | 2023-2024 | Apokyn, Apokyn |
| Lilly USA, LLC | $630.07 | 2022-2024 | Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $454.09 | 2023-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $451.50 | 2021-2024 | |
| Argenx US, INC. | $424.73 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $374.77 | 2022-2024 | Soliris, Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $350.47 | 2021-2024 | Hyqvia, Gammagard |
| Scilex Pharmaceuticals INC. | $339.75 | 2023-2024 | Ztlido |
| Harmony Biosciences LLC | $305.85 | 2023-2024 | Wakix |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $258.54 | 2022-2024 | |
| Acadia Pharmaceuticals INC | $257.07 | 2022-2024 | Nuplazid |
| Neurelis, INC. | $217.81 | 2022-2024 | Valtoco |
| Biogen, INC. | $204.45 | 2023-2024 | Vumerity, Tysabri, Plegridy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.92 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.37 | 2025 | Caplyta |
| Alkermes, INC. | $178.62 | 2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $165.66 | 2023-2025 | Ingrezza, Ongentys |
| Amgen INC. | $154.98 | 2022-2023 | Aimovig |
| Alnylam Pharmaceuticals INC. | $148.65 | 2023-2024 | Onpattro, Givlaari |
| Octapharma USA, INC. | $129.31 | 2023-2024 | Panzyga |
| Biohaven Pharmaceutical Holding Company LTD. | $119.53 | 2022 | |
| Sk Life Science, INC. | $102.12 | 2022-2023 | |
| Kyowa Kirin, INC. | $94.98 | 2023-2024 | Nourianz |
| Genentech USA, INC. | $87.40 | 2023-2024 | Ocrevus, Evrysdi |
| Celgene Corporation | $84.87 | 2021-2023 | Zeposia |
| Csl Behring | $75.18 | 2022-2023 | Hizentra |
| Almatica Pharma LLC | $73.55 | 2022-2023 | Gralise |
| Bio Products Laboratory USA, INC. | $70.12 | 2023 | Gammaplex, Coagadex |
| Avion Pharmaceuticals | $66.78 | 2023 | Dhivy |
| Redhill Biopharma INC. | $62.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $50.60 | 2022-2023 | Xarelto |
| Amneal Pharmaceuticals LLC | $48.00 | 2023-2024 | Rytary, Lyvispah |
| Intercept Pharmaceuticals, INC. | $46.35 | 2021 | |
| Supernus Pharmaceuticals, INC. | $44.37 | 2025 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $44.26 | 2025 | |
| Corium, LLC | $41.71 | 2023 | Adlarity |
| Impel Pharmaceuticals INC. | $38.83 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $35.42 | 2024-2025 | Rexulti, Nuedexta |
| Braintree Laboratories, INC. | $29.56 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.60 | 2025 | Fanapt, Hetlioz |
| Acorda Therapeutics, INC | $25.65 | 2023 | Inbrija |
| Jazz Pharmaceuticals INC. | $25.61 | 2023 | |
| Janssen Biotech, INC. | $23.19 | 2021 | |
| Uswm, LLC | $21.06 | 2025 | Iwilfin |
| Merck Sharp & Dohme LLC | $21.03 | 2023 | Welireg |
| Sumitomo Pharma America, INC. | $20.87 | 2023 | Aptiom |
| Upsher-Smith Laboratories LLC | $20.81 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.20 | 2022 | |
| Sandoz INC. | $15.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Miranda-Pasqualini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.